NewAmsterdam Pharma
A Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.
Latest NewAmsterdam Pharma News & Features
3 April 2024
5 January 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze